Autoimmune hepatitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 03 Aug 2026 10:26:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Autoimmune hepatitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of VAY736 for Patients with Autoimmune Hepatitis Who Do Not Respond Well to Standard Treatment https://clinicaltrials.eu/trial/study-on-the-effects-of-vay736-for-patients-with-autoimmune-hepatitis-who-do-not-respond-well-to-standard-treatment/ Mon, 03 Aug 2026 10:26:14 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-vay736-for-patients-with-autoimmune-hepatitis-who-do-not-respond-well-to-standard-treatment/ This clinical trial is focused on studying autoimmune hepatitis, a condition where the body’s immune system mistakenly attacks the liver. The study is investigating a treatment called VAY736, also known as ianalumab, which is a type of protein designed to target specific parts of the immune system. The trial will compare the effects of VAY736 with a placebo to see if it can help patients who have not responded well to or cannot tolerate standard treatments.

The purpose of the study is to evaluate the safety and effectiveness of VAY736 in improving liver function in patients with autoimmune hepatitis. The study is divided into two parts. In the first part, researchers will determine the best dose of VAY736 by observing its effects on liver enzyme levels over 24 weeks. In the second part, the chosen dose will be tested further to confirm its benefits and safety for patients.

Participants in the study will receive either VAY736 or a placebo through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor changes in liver health and any side effects experienced by participants. The goal is to find a new treatment option for those with autoimmune hepatitis who have limited success with existing therapies.

]]>